ITabMed Formed as JV to Develop T Cell Engagers; Raises $20 Million

Shanghai ITabMed announced it has completed the spin-off from Evive Biotech of the iTAb™ (immunotherapy antibody) platform and closed a $20 million Series A-round financing. Earlier this year, Evive (formerly Generon BioMed) and Dr. Xiaoqiang Yan formed ITabMed as a joint venture with full support from Evive. The JV will focus on continued development of oncology immunotherapies derived from the iTAb™ platform, which generates bi- or tri-specific T cell engagers. The company has started Phase I trials of two products while other iTAb drug candidates are in preclinical development. More details.... Share this with colleagues: // //